What are the clinical manifestations and recommended treatment for Cryptococcus species infection?

Cryptococcus Species: Clinical Manifestations and Treatment

Cryptococcosis presents most commonly as meningoencephalitis or pulmonary disease, with treatment stratified by anatomical site, disease severity, and immune status—ranging from fluconazole monotherapy for mild pulmonary disease to amphotericin B plus flucytosine for CNS involvement.

Clinical Manifestations

Central Nervous System Disease

Cryptococcal meningoencephalitis presents with insidious onset of:

• Headaches (most common)
• Fever
• Mental status changes
• Altered consciousness

The presentation may be subtle, particularly in immunocompromised patients, making a high index of suspicion critical 1.

Pulmonary Disease

Pulmonary cryptococcosis ranges from asymptomatic infection to severe ARDS 2. Symptoms are nonspecific and include:

• Fever and chills
• Cough (often nonproductive)
• Malaise and night sweats
• Dyspnea
• Weight loss
• Hemoptysis (less common)

Critical caveat: Radiographic findings are nonspecific—nodules are most common, but consolidation, cavitary lesions, and diffuse interstitial patterns can occur 1, 3. Diffuse interstitial pneumonia on imaging suggests poorer prognosis 2.

Other Manifestations

• Cutaneous involvement: Can represent disseminated disease (secondary) or primary cutaneous infection from direct inoculation 4, 5
• Disseminated disease: Multiple noncontiguous sites or high fungal burden (cryptococcal antigen ≥1:512) 2

Diagnostic Approach

Essential Workup Based on Immune Status

For immunosuppressed patients with pulmonary cryptococcosis:

• Always perform lumbar puncture to rule out CNS disease, as this fundamentally changes treatment duration and intensity 2
• Obtain blood cultures and serum cryptococcal antigen
• Measure CSF cryptococcal antigen if LP performed
• This is especially critical in HIV patients with CD4+ <200 cells/μL 2

For immunocompetent patients with pulmonary disease:

• Consider lumbar puncture for asymptomatic CNS involvement
• Can avoid LP if patient has asymptomatic pulmonary nodule/infiltrate, no CNS symptoms, and negative or very low serum cryptococcal antigen 2

Opening pressure measurement during LP is mandatory for all patients with suspected or proven cryptococcosis, as elevated intracranial pressure is a major determinant of morbidity and mortality 1.

Treatment Recommendations

CNS Disease (Meningoencephalitis)

HIV-Infected Patients

Induction (2 weeks):

• Amphotericin B deoxycholate (0.7-1.0 mg/kg/day IV) PLUS flucytosine (100 mg/kg/day PO in 4 divided doses) 2
• Alternative: Liposomal amphotericin B (3-4 mg/kg/day) or ABLC (5 mg/kg/day) plus flucytosine 2

Consolidation (8 weeks):

• Fluconazole 400 mg/day 2

Maintenance (≥1 year):

• Fluconazole 200 mg/day until CD4 >100 cells/μL for ≥3 months on HAART with undetectable viral load 2

Timing of HAART: Initiate 2-10 weeks after starting antifungal therapy 2

Transplant Recipients

Induction (≥2 weeks):

• Liposomal amphotericin B (3-4 mg/kg/day) OR ABLC (5 mg/kg/day) PLUS flucytosine (100 mg/kg/day) 2
• If no flucytosine, extend liposomal amphotericin B to 4-6 weeks
• Consider higher dose (6 mg/kg/day) for high fungal burden or relapse 2

Important: Amphotericin B deoxycholate should be used with extreme caution due to nephrotoxicity with calcineurin inhibitors 2

Consolidation (6-12 months):

• Fluconazole 400-800 mg/day 2

Maintenance:

• Fluconazole 200-400 mg/day for ≥6-12 months 2
• Stepwise reduction of immunosuppression, lowering corticosteroids first 2

Non-HIV, Non-Transplant Patients

Induction:

• Amphotericin B deoxycholate (0.7-1.0 mg/kg/day) PLUS flucytosine (100 mg/kg/day) for ≥4 weeks 2
• 4 weeks reserved for uncomplicated meningitis with negative CSF culture at 2 weeks
• Extend to 6 weeks for neurological complications 2
• Low-risk patients may use 2-week induction followed by high-dose fluconazole (800 mg/day) for 8 weeks 2

Consolidation (8 weeks):

• Fluconazole 400-800 mg/day 2

Maintenance (6-12 months):

• Fluconazole 200 mg/day 2

Cerebral Cryptococcomas

Induction (≥6 weeks):

• Amphotericin B (0.7-1 mg/kg/day) OR liposomal amphotericin B (3-4 mg/kg/day) OR ABLC (5 mg/kg/day) PLUS flucytosine (100 mg/kg/day) 2

Consolidation/Maintenance (6-18 months):

• Fluconazole 400-800 mg/day 2

Adjunctive therapy:

• Corticosteroids for mass effect and edema 2
• Surgery for lesions ≥3 cm with mass effect: Consider open or stereotactic debulking 2

Pulmonary Disease

Immunosuppressed Patients

Severe pneumonia (ARDS) or CNS/disseminated disease:

• Treat as CNS disease (see above) 2

Mild-to-moderate disease (no diffuse infiltrates, no severe immunosuppression, negative dissemination workup):

• Fluconazole 400 mg (6 mg/kg) daily for 6-12 months 2
• In HIV patients on HAART with CD4 >100 cells/μL and cryptococcal antigen ≤1:512, consider stopping after 1 year 2

ARDS in IRIS context:

• Consider corticosteroids 2

Immunocompetent Patients

Mild-to-moderate disease:

• Fluconazole 400 mg daily for 6-12 months 2
• Persistently positive serum antigen is NOT an indication to continue therapy 2

Alternatives (if fluconazole unavailable/contraindicated):

• Itraconazole 200 mg twice daily
• Voriconazole 200 mg twice daily
• Posaconazole 400 mg twice daily 2

Severe disease:

• Treat as CNS disease 2

Surgery indications:

• Persistent radiographic abnormalities not responding to therapy
• Diagnostic purposes 2

Disseminated Non-CNS Disease

High fungal burden (cryptococcemia, ≥2 noncontiguous sites, or antigen ≥1:512):

• Treat as CNS disease 2

Single site, no fungemia, no immunosuppression, CNS ruled out:

• Fluconazole 400 mg (6 mg/kg) daily for 6-12 months 2

Critical Management Issues

Elevated Intracranial Pressure

This is a major cause of mortality and requires aggressive management:

Initial management:

• Therapeutic lumbar puncture to reduce opening pressure to <20 cm H₂O or remove 20-30 mL CSF 1
• Repeat daily or more frequently if symptoms persist
• Avoid acetazolamide and corticosteroids (unless for IRIS) 2

Persistent elevation:

• Consider ventriculoperitoneal shunt if pressure remains elevated despite frequent drainage 2

Immune Reconstitution Inflammatory Syndrome (IRIS)

Minor manifestations:

• No specific treatment needed; resolve spontaneously in days to weeks 2

Major complications (CNS inflammation with increased ICP):

• Corticosteroids: prednisone 0.5-1.0 mg/kg/day (or dexamethasone for severe CNS symptoms) 2
• Taper over 2-6 weeks while continuing antifungals 2
• Do not alter antifungal therapy 2

Special Populations

Pregnant women:

• Amphotericin B deoxycholate or liposomal amphotericin B with or without flucytosine (Category C—weigh risk vs. benefit) 2
• Start fluconazole after delivery; avoid first trimester exposure 2
• For stable pulmonary disease, close follow-up with fluconazole after delivery 2

Common Pitfalls

1. Failing to perform LP in immunosuppressed patients with pulmonary disease: This misses CNS involvement in up to 30% of cases, leading to inadequate treatment duration 2

2. Not measuring opening pressure during LP: Elevated ICP is the primary driver of mortality and requires specific management beyond antifungals 1

3. Inadequate induction duration in non-HIV patients: These patients often require longer induction (4-6 weeks vs. 2 weeks in HIV) due to different immune responses 2

4. Misinterpreting IRIS as treatment failure: Worsening symptoms after immune reconstitution may represent IRIS, not fungal progression—do not stop antifungals 2

5. Using amphotericin B deoxycholate in transplant recipients: High nephrotoxicity risk with calcineurin inhibitors; liposomal formulations are strongly preferred 2

6. Continuing fluconazole based on persistent positive antigen titers alone: In immunocompetent patients with pulmonary disease, antigen persistence is not an indication to extend therapy 2